nodes	percent_of_prediction	percent_of_DWPC	metapath
Moclobemide—Rectal tenesmus—Epirubicin—bone cancer	0.018	0.023	CcSEcCtD
Moclobemide—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.0176	0.0849	CbGpPWpGaD
Moclobemide—Rectal tenesmus—Doxorubicin—bone cancer	0.0166	0.0213	CcSEcCtD
Moclobemide—Appetite absent—Methotrexate—bone cancer	0.0144	0.0184	CcSEcCtD
Moclobemide—Proctalgia—Epirubicin—bone cancer	0.0143	0.0183	CcSEcCtD
Moclobemide—Dysarthria—Cisplatin—bone cancer	0.0138	0.0177	CcSEcCtD
Moclobemide—Proctalgia—Doxorubicin—bone cancer	0.0132	0.0169	CcSEcCtD
Moclobemide—Anorectal discomfort—Epirubicin—bone cancer	0.0122	0.0157	CcSEcCtD
Moclobemide—Anorectal discomfort—Doxorubicin—bone cancer	0.0113	0.0145	CcSEcCtD
Moclobemide—Polyuria—Cisplatin—bone cancer	0.0108	0.0138	CcSEcCtD
Moclobemide—Gingivitis—Methotrexate—bone cancer	0.00912	0.0117	CcSEcCtD
Moclobemide—Dermatitis atopic—Epirubicin—bone cancer	0.00905	0.0116	CcSEcCtD
Moclobemide—Irritability—Cisplatin—bone cancer	0.00904	0.0116	CcSEcCtD
Moclobemide—Gingivitis—Epirubicin—bone cancer	0.00853	0.0109	CcSEcCtD
Moclobemide—Dermatitis atopic—Doxorubicin—bone cancer	0.00837	0.0107	CcSEcCtD
Moclobemide—Gingivitis—Doxorubicin—bone cancer	0.0079	0.0101	CcSEcCtD
Moclobemide—Dysarthria—Methotrexate—bone cancer	0.00757	0.00969	CcSEcCtD
Moclobemide—Hepatic enzyme increased—Methotrexate—bone cancer	0.00757	0.00969	CcSEcCtD
Moclobemide—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00742	0.0358	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—FEV—bone cancer	0.0074	0.0357	CbGpPWpGaD
Moclobemide—Bezafibrate—CYP3A4—bone cancer	0.00727	0.607	CrCbGaD
Moclobemide—Stomatitis—Cisplatin—bone cancer	0.00711	0.00911	CcSEcCtD
Moclobemide—Conjunctivitis—Cisplatin—bone cancer	0.00709	0.00908	CcSEcCtD
Moclobemide—Dysarthria—Epirubicin—bone cancer	0.00708	0.00907	CcSEcCtD
Moclobemide—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00686	0.0331	CbGpPWpGaD
Moclobemide—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00683	0.0329	CbGpPWpGaD
Moclobemide—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00677	0.0326	CbGpPWpGaD
Moclobemide—Bradycardia—Cisplatin—bone cancer	0.00667	0.00854	CcSEcCtD
Moclobemide—Dysarthria—Doxorubicin—bone cancer	0.00655	0.00839	CcSEcCtD
Moclobemide—Urine output increased—Methotrexate—bone cancer	0.00647	0.00829	CcSEcCtD
Moclobemide—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00647	0.0312	CbGpPWpGaD
Moclobemide—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.00646	0.0312	CbGpPWpGaD
Moclobemide—Visual impairment—Cisplatin—bone cancer	0.00631	0.00808	CcSEcCtD
Moclobemide—MAOB—Tryptophan metabolism—CYP3A4—bone cancer	0.00619	0.0299	CbGpPWpGaD
Moclobemide—Tinnitus—Cisplatin—bone cancer	0.00611	0.00782	CcSEcCtD
Moclobemide—Flushing—Cisplatin—bone cancer	0.00608	0.00779	CcSEcCtD
Moclobemide—Polyuria—Methotrexate—bone cancer	0.00592	0.00758	CcSEcCtD
Moclobemide—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00578	0.0279	CbGpPWpGaD
Moclobemide—Flatulence—Cisplatin—bone cancer	0.00562	0.0072	CcSEcCtD
Moclobemide—Visual disturbance—Methotrexate—bone cancer	0.00548	0.00702	CcSEcCtD
Moclobemide—Vision blurred—Cisplatin—bone cancer	0.00537	0.00688	CcSEcCtD
Moclobemide—Tremor—Cisplatin—bone cancer	0.00534	0.00684	CcSEcCtD
Moclobemide—Ill-defined disorder—Cisplatin—bone cancer	0.00529	0.00678	CcSEcCtD
Moclobemide—Hot flush—Epirubicin—bone cancer	0.0052	0.00666	CcSEcCtD
Moclobemide—Osteoarthritis—Methotrexate—bone cancer	0.00519	0.00665	CcSEcCtD
Moclobemide—Menopausal symptoms—Epirubicin—bone cancer	0.00515	0.0066	CcSEcCtD
Moclobemide—Malaise—Cisplatin—bone cancer	0.00514	0.00659	CcSEcCtD
Moclobemide—Irritability—Methotrexate—bone cancer	0.00496	0.00635	CcSEcCtD
Moclobemide—Osteoarthritis—Epirubicin—bone cancer	0.00486	0.00623	CcSEcCtD
Moclobemide—Myalgia—Cisplatin—bone cancer	0.00485	0.00622	CcSEcCtD
Moclobemide—Anxiety—Cisplatin—bone cancer	0.00484	0.0062	CcSEcCtD
Moclobemide—Hot flush—Doxorubicin—bone cancer	0.00481	0.00616	CcSEcCtD
Moclobemide—Discomfort—Cisplatin—bone cancer	0.0048	0.00614	CcSEcCtD
Moclobemide—Migraine—Epirubicin—bone cancer	0.00479	0.00613	CcSEcCtD
Moclobemide—Menopausal symptoms—Doxorubicin—bone cancer	0.00477	0.00611	CcSEcCtD
Moclobemide—Haloperidol—CYP3A4—bone cancer	0.00471	0.393	CrCbGaD
Moclobemide—Tachycardia—Cisplatin—bone cancer	0.00454	0.00582	CcSEcCtD
Moclobemide—Osteoarthritis—Doxorubicin—bone cancer	0.0045	0.00576	CcSEcCtD
Moclobemide—Hyperhidrosis—Cisplatin—bone cancer	0.0045	0.00576	CcSEcCtD
Moclobemide—Dry skin—Epirubicin—bone cancer	0.00446	0.00571	CcSEcCtD
Moclobemide—Migraine—Doxorubicin—bone cancer	0.00443	0.00567	CcSEcCtD
Moclobemide—Hypotension—Cisplatin—bone cancer	0.00435	0.00557	CcSEcCtD
Moclobemide—Gastritis—Epirubicin—bone cancer	0.0043	0.00551	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00424	0.00543	CcSEcCtD
Moclobemide—Abdominal distension—Epirubicin—bone cancer	0.00423	0.00542	CcSEcCtD
Moclobemide—Dysuria—Methotrexate—bone cancer	0.0042	0.00538	CcSEcCtD
Moclobemide—Paraesthesia—Cisplatin—bone cancer	0.00418	0.00535	CcSEcCtD
Moclobemide—Dyspnoea—Cisplatin—bone cancer	0.00415	0.00531	CcSEcCtD
Moclobemide—Dry skin—Doxorubicin—bone cancer	0.00412	0.00528	CcSEcCtD
Moclobemide—Angina pectoris—Epirubicin—bone cancer	0.00409	0.00524	CcSEcCtD
Moclobemide—MAOB—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00406	0.0196	CbGpPWpGaD
Moclobemide—Decreased appetite—Cisplatin—bone cancer	0.00404	0.00518	CcSEcCtD
Moclobemide—Drowsiness—Methotrexate—bone cancer	0.004	0.00513	CcSEcCtD
Moclobemide—Gastritis—Doxorubicin—bone cancer	0.00398	0.0051	CcSEcCtD
Moclobemide—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00394	0.019	CbGpPWpGaD
Moclobemide—Dysuria—Epirubicin—bone cancer	0.00393	0.00503	CcSEcCtD
Moclobemide—Abdominal distension—Doxorubicin—bone cancer	0.00391	0.00501	CcSEcCtD
Moclobemide—Stomatitis—Methotrexate—bone cancer	0.0039	0.005	CcSEcCtD
Moclobemide—Conjunctivitis—Methotrexate—bone cancer	0.00389	0.00498	CcSEcCtD
Moclobemide—Sweating—Methotrexate—bone cancer	0.00384	0.00492	CcSEcCtD
Moclobemide—Feeling abnormal—Cisplatin—bone cancer	0.00383	0.00491	CcSEcCtD
Moclobemide—Angina pectoris—Doxorubicin—bone cancer	0.00379	0.00485	CcSEcCtD
Moclobemide—Drowsiness—Epirubicin—bone cancer	0.00375	0.0048	CcSEcCtD
Moclobemide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00366	0.0176	CbGpPWpGaD
Moclobemide—Stomatitis—Epirubicin—bone cancer	0.00365	0.00468	CcSEcCtD
Moclobemide—Conjunctivitis—Epirubicin—bone cancer	0.00364	0.00466	CcSEcCtD
Moclobemide—Dysuria—Doxorubicin—bone cancer	0.00364	0.00466	CcSEcCtD
Moclobemide—Sweating—Epirubicin—bone cancer	0.00359	0.0046	CcSEcCtD
Moclobemide—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.00358	0.0173	CbGpPWpGaD
Moclobemide—Drowsiness—Doxorubicin—bone cancer	0.00347	0.00444	CcSEcCtD
Moclobemide—Visual impairment—Methotrexate—bone cancer	0.00346	0.00444	CcSEcCtD
Moclobemide—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.00344	0.0166	CbGpPWpGaD
Moclobemide—Bradycardia—Epirubicin—bone cancer	0.00342	0.00439	CcSEcCtD
Moclobemide—Stomatitis—Doxorubicin—bone cancer	0.00338	0.00433	CcSEcCtD
Moclobemide—Conjunctivitis—Doxorubicin—bone cancer	0.00337	0.00432	CcSEcCtD
Moclobemide—Tinnitus—Methotrexate—bone cancer	0.00335	0.00429	CcSEcCtD
Moclobemide—Asthenia—Cisplatin—bone cancer	0.00334	0.00428	CcSEcCtD
Moclobemide—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00334	0.0161	CbGpPWpGaD
Moclobemide—Sweating—Doxorubicin—bone cancer	0.00332	0.00426	CcSEcCtD
Moclobemide—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.00329	0.0159	CbGpPWpGaD
Moclobemide—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.00327	0.0157	CbGpPWpGaD
Moclobemide—Visual impairment—Epirubicin—bone cancer	0.00324	0.00415	CcSEcCtD
Moclobemide—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.00319	0.0154	CbGpPWpGaD
Moclobemide—Diarrhoea—Cisplatin—bone cancer	0.00318	0.00408	CcSEcCtD
Moclobemide—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.00317	0.0153	CbGpPWpGaD
Moclobemide—Bradycardia—Doxorubicin—bone cancer	0.00317	0.00406	CcSEcCtD
Moclobemide—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.00314	0.0151	CbGpPWpGaD
Moclobemide—Tinnitus—Epirubicin—bone cancer	0.00314	0.00402	CcSEcCtD
Moclobemide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00312	0.0151	CbGpPWpGaD
Moclobemide—Flushing—Epirubicin—bone cancer	0.00312	0.004	CcSEcCtD
Moclobemide—Dysgeusia—Methotrexate—bone cancer	0.00306	0.00392	CcSEcCtD
Moclobemide—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.00304	0.0146	CbGpPWpGaD
Moclobemide—Visual impairment—Doxorubicin—bone cancer	0.003	0.00384	CcSEcCtD
Moclobemide—Vomiting—Cisplatin—bone cancer	0.00296	0.00379	CcSEcCtD
Moclobemide—Vision blurred—Methotrexate—bone cancer	0.00295	0.00378	CcSEcCtD
Moclobemide—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.00294	0.0142	CbGpPWpGaD
Moclobemide—Rash—Cisplatin—bone cancer	0.00293	0.00376	CcSEcCtD
Moclobemide—Dermatitis—Cisplatin—bone cancer	0.00293	0.00375	CcSEcCtD
Moclobemide—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.00291	0.014	CbGpPWpGaD
Moclobemide—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.00291	0.014	CbGpPWpGaD
Moclobemide—Ill-defined disorder—Methotrexate—bone cancer	0.0029	0.00372	CcSEcCtD
Moclobemide—Tinnitus—Doxorubicin—bone cancer	0.0029	0.00372	CcSEcCtD
Moclobemide—Flushing—Doxorubicin—bone cancer	0.00289	0.0037	CcSEcCtD
Moclobemide—Flatulence—Epirubicin—bone cancer	0.00288	0.0037	CcSEcCtD
Moclobemide—Tension—Epirubicin—bone cancer	0.00287	0.00368	CcSEcCtD
Moclobemide—Dysgeusia—Epirubicin—bone cancer	0.00287	0.00367	CcSEcCtD
Moclobemide—MAOB—Tryptophan metabolism—MDM2—bone cancer	0.00285	0.0137	CbGpPWpGaD
Moclobemide—Nervousness—Epirubicin—bone cancer	0.00284	0.00364	CcSEcCtD
Moclobemide—Malaise—Methotrexate—bone cancer	0.00282	0.00361	CcSEcCtD
Moclobemide—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.00279	0.0135	CbGpPWpGaD
Moclobemide—Nausea—Cisplatin—bone cancer	0.00276	0.00354	CcSEcCtD
Moclobemide—Vision blurred—Epirubicin—bone cancer	0.00276	0.00353	CcSEcCtD
Moclobemide—Ill-defined disorder—Epirubicin—bone cancer	0.00272	0.00348	CcSEcCtD
Moclobemide—Agitation—Epirubicin—bone cancer	0.00269	0.00345	CcSEcCtD
Moclobemide—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.00268	0.0129	CbGpPWpGaD
Moclobemide—Flatulence—Doxorubicin—bone cancer	0.00267	0.00342	CcSEcCtD
Moclobemide—Chest pain—Methotrexate—bone cancer	0.00266	0.00341	CcSEcCtD
Moclobemide—Myalgia—Methotrexate—bone cancer	0.00266	0.00341	CcSEcCtD
Moclobemide—Tension—Doxorubicin—bone cancer	0.00266	0.00341	CcSEcCtD
Moclobemide—Dysgeusia—Doxorubicin—bone cancer	0.00265	0.0034	CcSEcCtD
Moclobemide—Malaise—Epirubicin—bone cancer	0.00264	0.00338	CcSEcCtD
Moclobemide—Discomfort—Methotrexate—bone cancer	0.00263	0.00337	CcSEcCtD
Moclobemide—Nervousness—Doxorubicin—bone cancer	0.00263	0.00337	CcSEcCtD
Moclobemide—Syncope—Epirubicin—bone cancer	0.00263	0.00336	CcSEcCtD
Moclobemide—Palpitations—Epirubicin—bone cancer	0.00259	0.00331	CcSEcCtD
Moclobemide—Confusional state—Methotrexate—bone cancer	0.00257	0.0033	CcSEcCtD
Moclobemide—Loss of consciousness—Epirubicin—bone cancer	0.00257	0.0033	CcSEcCtD
Moclobemide—Vision blurred—Doxorubicin—bone cancer	0.00255	0.00327	CcSEcCtD
Moclobemide—MAOA—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00255	0.0123	CbGpPWpGaD
Moclobemide—Hypertension—Epirubicin—bone cancer	0.00253	0.00324	CcSEcCtD
Moclobemide—Ill-defined disorder—Doxorubicin—bone cancer	0.00251	0.00322	CcSEcCtD
Moclobemide—Myalgia—Epirubicin—bone cancer	0.00249	0.00319	CcSEcCtD
Moclobemide—Chest pain—Epirubicin—bone cancer	0.00249	0.00319	CcSEcCtD
Moclobemide—Agitation—Doxorubicin—bone cancer	0.00249	0.00319	CcSEcCtD
Moclobemide—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.00249	0.012	CbGpPWpGaD
Moclobemide—Anxiety—Epirubicin—bone cancer	0.00248	0.00318	CcSEcCtD
Moclobemide—Hyperhidrosis—Methotrexate—bone cancer	0.00247	0.00316	CcSEcCtD
Moclobemide—Discomfort—Epirubicin—bone cancer	0.00246	0.00315	CcSEcCtD
Moclobemide—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00246	0.0119	CbGpPWpGaD
Moclobemide—Malaise—Doxorubicin—bone cancer	0.00244	0.00313	CcSEcCtD
Moclobemide—Dry mouth—Epirubicin—bone cancer	0.00244	0.00312	CcSEcCtD
Moclobemide—Syncope—Doxorubicin—bone cancer	0.00243	0.00311	CcSEcCtD
Moclobemide—Confusional state—Epirubicin—bone cancer	0.00241	0.00309	CcSEcCtD
Moclobemide—Palpitations—Doxorubicin—bone cancer	0.00239	0.00307	CcSEcCtD
Moclobemide—Hypotension—Methotrexate—bone cancer	0.00239	0.00306	CcSEcCtD
Moclobemide—Loss of consciousness—Doxorubicin—bone cancer	0.00238	0.00305	CcSEcCtD
Moclobemide—Shock—Epirubicin—bone cancer	0.00235	0.00301	CcSEcCtD
Moclobemide—Hypertension—Doxorubicin—bone cancer	0.00234	0.003	CcSEcCtD
Moclobemide—Tachycardia—Epirubicin—bone cancer	0.00233	0.00299	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00233	0.00298	CcSEcCtD
Moclobemide—Hyperhidrosis—Epirubicin—bone cancer	0.00231	0.00296	CcSEcCtD
Moclobemide—Insomnia—Methotrexate—bone cancer	0.00231	0.00296	CcSEcCtD
Moclobemide—Chest pain—Doxorubicin—bone cancer	0.00231	0.00295	CcSEcCtD
Moclobemide—Myalgia—Doxorubicin—bone cancer	0.00231	0.00295	CcSEcCtD
Moclobemide—Anxiety—Doxorubicin—bone cancer	0.0023	0.00294	CcSEcCtD
Moclobemide—Paraesthesia—Methotrexate—bone cancer	0.00229	0.00294	CcSEcCtD
Moclobemide—Discomfort—Doxorubicin—bone cancer	0.00228	0.00292	CcSEcCtD
Moclobemide—Dyspnoea—Methotrexate—bone cancer	0.00228	0.00292	CcSEcCtD
Moclobemide—Somnolence—Methotrexate—bone cancer	0.00227	0.00291	CcSEcCtD
Moclobemide—Dry mouth—Doxorubicin—bone cancer	0.00226	0.00289	CcSEcCtD
Moclobemide—Dyspepsia—Methotrexate—bone cancer	0.00225	0.00288	CcSEcCtD
Moclobemide—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00224	0.0108	CbGpPWpGaD
Moclobemide—Hypotension—Epirubicin—bone cancer	0.00223	0.00286	CcSEcCtD
Moclobemide—Confusional state—Doxorubicin—bone cancer	0.00223	0.00286	CcSEcCtD
Moclobemide—Decreased appetite—Methotrexate—bone cancer	0.00222	0.00284	CcSEcCtD
Moclobemide—Fatigue—Methotrexate—bone cancer	0.0022	0.00282	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00218	0.00279	CcSEcCtD
Moclobemide—Shock—Doxorubicin—bone cancer	0.00218	0.00279	CcSEcCtD
Moclobemide—Insomnia—Epirubicin—bone cancer	0.00216	0.00277	CcSEcCtD
Moclobemide—Tachycardia—Doxorubicin—bone cancer	0.00216	0.00276	CcSEcCtD
Moclobemide—MAOB—Biological oxidations—CYP3A4—bone cancer	0.00216	0.0104	CbGpPWpGaD
Moclobemide—Paraesthesia—Epirubicin—bone cancer	0.00215	0.00275	CcSEcCtD
Moclobemide—Hyperhidrosis—Doxorubicin—bone cancer	0.00214	0.00274	CcSEcCtD
Moclobemide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00214	0.0103	CbGpPWpGaD
Moclobemide—Dyspnoea—Epirubicin—bone cancer	0.00213	0.00273	CcSEcCtD
Moclobemide—Somnolence—Epirubicin—bone cancer	0.00212	0.00272	CcSEcCtD
Moclobemide—Feeling abnormal—Methotrexate—bone cancer	0.0021	0.0027	CcSEcCtD
Moclobemide—Dyspepsia—Epirubicin—bone cancer	0.0021	0.00269	CcSEcCtD
Moclobemide—Gastrointestinal pain—Methotrexate—bone cancer	0.00209	0.00267	CcSEcCtD
Moclobemide—Decreased appetite—Epirubicin—bone cancer	0.00208	0.00266	CcSEcCtD
Moclobemide—Hypotension—Doxorubicin—bone cancer	0.00207	0.00265	CcSEcCtD
Moclobemide—Fatigue—Epirubicin—bone cancer	0.00206	0.00264	CcSEcCtD
Moclobemide—Constipation—Epirubicin—bone cancer	0.00204	0.00262	CcSEcCtD
Moclobemide—Urticaria—Methotrexate—bone cancer	0.00203	0.0026	CcSEcCtD
Moclobemide—Abdominal pain—Methotrexate—bone cancer	0.00202	0.00259	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00201	0.00258	CcSEcCtD
Moclobemide—Insomnia—Doxorubicin—bone cancer	0.002	0.00256	CcSEcCtD
Moclobemide—Paraesthesia—Doxorubicin—bone cancer	0.00199	0.00254	CcSEcCtD
Moclobemide—Dyspnoea—Doxorubicin—bone cancer	0.00197	0.00252	CcSEcCtD
Moclobemide—Feeling abnormal—Epirubicin—bone cancer	0.00197	0.00252	CcSEcCtD
Moclobemide—Somnolence—Doxorubicin—bone cancer	0.00197	0.00252	CcSEcCtD
Moclobemide—Gastrointestinal pain—Epirubicin—bone cancer	0.00195	0.0025	CcSEcCtD
Moclobemide—Dyspepsia—Doxorubicin—bone cancer	0.00195	0.00249	CcSEcCtD
Moclobemide—Decreased appetite—Doxorubicin—bone cancer	0.00192	0.00246	CcSEcCtD
Moclobemide—Fatigue—Doxorubicin—bone cancer	0.00191	0.00244	CcSEcCtD
Moclobemide—Urticaria—Epirubicin—bone cancer	0.0019	0.00243	CcSEcCtD
Moclobemide—Constipation—Doxorubicin—bone cancer	0.00189	0.00242	CcSEcCtD
Moclobemide—Abdominal pain—Epirubicin—bone cancer	0.00189	0.00242	CcSEcCtD
Moclobemide—MAOB—Biological oxidations—GSTP1—bone cancer	0.00184	0.00889	CbGpPWpGaD
Moclobemide—Asthenia—Methotrexate—bone cancer	0.00183	0.00235	CcSEcCtD
Moclobemide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00183	0.0088	CbGpPWpGaD
Moclobemide—Feeling abnormal—Doxorubicin—bone cancer	0.00182	0.00233	CcSEcCtD
Moclobemide—Gastrointestinal pain—Doxorubicin—bone cancer	0.00181	0.00232	CcSEcCtD
Moclobemide—Pruritus—Methotrexate—bone cancer	0.00181	0.00231	CcSEcCtD
Moclobemide—Urticaria—Doxorubicin—bone cancer	0.00176	0.00225	CcSEcCtD
Moclobemide—Abdominal pain—Doxorubicin—bone cancer	0.00175	0.00224	CcSEcCtD
Moclobemide—Diarrhoea—Methotrexate—bone cancer	0.00175	0.00224	CcSEcCtD
Moclobemide—Asthenia—Epirubicin—bone cancer	0.00171	0.0022	CcSEcCtD
Moclobemide—Pruritus—Epirubicin—bone cancer	0.00169	0.00217	CcSEcCtD
Moclobemide—Dizziness—Methotrexate—bone cancer	0.00169	0.00216	CcSEcCtD
Moclobemide—Diarrhoea—Epirubicin—bone cancer	0.00163	0.00209	CcSEcCtD
Moclobemide—Vomiting—Methotrexate—bone cancer	0.00162	0.00208	CcSEcCtD
Moclobemide—Rash—Methotrexate—bone cancer	0.00161	0.00206	CcSEcCtD
Moclobemide—Dermatitis—Methotrexate—bone cancer	0.00161	0.00206	CcSEcCtD
Moclobemide—Headache—Methotrexate—bone cancer	0.0016	0.00205	CcSEcCtD
Moclobemide—Asthenia—Doxorubicin—bone cancer	0.00159	0.00203	CcSEcCtD
Moclobemide—Dizziness—Epirubicin—bone cancer	0.00158	0.00202	CcSEcCtD
Moclobemide—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.00157	0.00759	CbGpPWpGaD
Moclobemide—Pruritus—Doxorubicin—bone cancer	0.00156	0.002	CcSEcCtD
Moclobemide—Vomiting—Epirubicin—bone cancer	0.00152	0.00195	CcSEcCtD
Moclobemide—Nausea—Methotrexate—bone cancer	0.00152	0.00194	CcSEcCtD
Moclobemide—Diarrhoea—Doxorubicin—bone cancer	0.00151	0.00194	CcSEcCtD
Moclobemide—Rash—Epirubicin—bone cancer	0.00151	0.00193	CcSEcCtD
Moclobemide—Dermatitis—Epirubicin—bone cancer	0.00151	0.00193	CcSEcCtD
Moclobemide—Headache—Epirubicin—bone cancer	0.0015	0.00192	CcSEcCtD
Moclobemide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00149	0.00717	CbGpPWpGaD
Moclobemide—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00147	0.00708	CbGpPWpGaD
Moclobemide—Dizziness—Doxorubicin—bone cancer	0.00146	0.00187	CcSEcCtD
Moclobemide—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.00143	0.00691	CbGpPWpGaD
Moclobemide—Nausea—Epirubicin—bone cancer	0.00142	0.00182	CcSEcCtD
Moclobemide—Vomiting—Doxorubicin—bone cancer	0.00141	0.0018	CcSEcCtD
Moclobemide—Rash—Doxorubicin—bone cancer	0.00139	0.00179	CcSEcCtD
Moclobemide—Dermatitis—Doxorubicin—bone cancer	0.00139	0.00178	CcSEcCtD
Moclobemide—Headache—Doxorubicin—bone cancer	0.00139	0.00177	CcSEcCtD
Moclobemide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00137	0.0066	CbGpPWpGaD
Moclobemide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00136	0.00654	CbGpPWpGaD
Moclobemide—MAOA—Biological oxidations—CYP3A4—bone cancer	0.00135	0.00652	CbGpPWpGaD
Moclobemide—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00135	0.00651	CbGpPWpGaD
Moclobemide—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00134	0.00645	CbGpPWpGaD
Moclobemide—Nausea—Doxorubicin—bone cancer	0.00131	0.00168	CcSEcCtD
Moclobemide—MAOB—Metabolism—NDUFA12—bone cancer	0.00129	0.00623	CbGpPWpGaD
Moclobemide—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00121	0.00581	CbGpPWpGaD
Moclobemide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00116	0.00559	CbGpPWpGaD
Moclobemide—MAOA—Biological oxidations—GSTP1—bone cancer	0.00116	0.00558	CbGpPWpGaD
Moclobemide—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00114	0.00551	CbGpPWpGaD
Moclobemide—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00111	0.00535	CbGpPWpGaD
Moclobemide—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.0011	0.0053	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—NT5C3A—bone cancer	0.00107	0.00516	CbGpPWpGaD
Moclobemide—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00094	0.00453	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—NDUFA12—bone cancer	0.000811	0.00391	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000773	0.00373	CbGpPWpGaD
Moclobemide—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000763	0.00368	CbGpPWpGaD
Moclobemide—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.00073	0.00352	CbGpPWpGaD
Moclobemide—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000695	0.00335	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—NT5C3A—bone cancer	0.000672	0.00324	CbGpPWpGaD
Moclobemide—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000659	0.00318	CbGpPWpGaD
Moclobemide—MAOA—Transmission across Chemical Synapses—BRAF—bone cancer	0.000658	0.00317	CbGpPWpGaD
Moclobemide—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.000641	0.00309	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000635	0.00306	CbGpPWpGaD
Moclobemide—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.000632	0.00305	CbGpPWpGaD
Moclobemide—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000594	0.00286	CbGpPWpGaD
Moclobemide—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000589	0.00284	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—JUN—bone cancer	0.000585	0.00282	CbGpPWpGaD
Moclobemide—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.000584	0.00282	CbGpPWpGaD
Moclobemide—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.000581	0.0028	CbGpPWpGaD
Moclobemide—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	0.000576	0.00278	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000573	0.00276	CbGpPWpGaD
Moclobemide—MAOA—Transmission across Chemical Synapses—MDM2—bone cancer	0.000551	0.00266	CbGpPWpGaD
Moclobemide—CYP2C19—Biological oxidations—GSTP1—bone cancer	0.000548	0.00264	CbGpPWpGaD
Moclobemide—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	0.00054	0.00261	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—BRAF—bone cancer	0.000504	0.00243	CbGpPWpGaD
Moclobemide—CYP2D6—Biological oxidations—GSTP1—bone cancer	0.000504	0.00243	CbGpPWpGaD
Moclobemide—CYP2C9—Biological oxidations—GSTP1—bone cancer	0.0005	0.00241	CbGpPWpGaD
Moclobemide—CYP1A2—Biological oxidations—CYP3A4—bone cancer	0.000499	0.00241	CbGpPWpGaD
Moclobemide—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	0.000497	0.0024	CbGpPWpGaD
Moclobemide—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	0.000493	0.00238	CbGpPWpGaD
Moclobemide—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	0.000492	0.00237	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—ENO2—bone cancer	0.000469	0.00226	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.00045	0.00217	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.00045	0.00217	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—DHFR—bone cancer	0.000435	0.0021	CbGpPWpGaD
Moclobemide—CYP1A2—Biological oxidations—GSTP1—bone cancer	0.000427	0.00206	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—MDM2—bone cancer	0.000422	0.00204	CbGpPWpGaD
Moclobemide—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	0.000421	0.00203	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—GNA11—bone cancer	0.000407	0.00196	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—NDUFA12—bone cancer	0.000384	0.00185	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—CYP3A4—bone cancer	0.000369	0.00178	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—NDUFA12—bone cancer	0.000353	0.0017	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—NDUFA12—bone cancer	0.00035	0.00169	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—NT5C3A—bone cancer	0.000318	0.00153	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—GSTP1—bone cancer	0.000315	0.00152	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—NDUFA12—bone cancer	0.000299	0.00144	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—ENO2—bone cancer	0.000294	0.00142	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—NT5C3A—bone cancer	0.000293	0.00141	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—NT5C3A—bone cancer	0.00029	0.0014	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—DHFR—bone cancer	0.000273	0.00132	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—GNA11—bone cancer	0.000255	0.00123	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—NT5C3A—bone cancer	0.000248	0.0012	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—CYP3A4—bone cancer	0.000231	0.00112	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—GSTP1—bone cancer	0.000198	0.000954	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—PTGS2—bone cancer	0.000163	0.000788	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—ENO2—bone cancer	0.000139	0.000672	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—DHFR—bone cancer	0.000129	0.000623	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—ENO2—bone cancer	0.000128	0.000618	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—ENO2—bone cancer	0.000127	0.000613	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—GNA11—bone cancer	0.000121	0.000583	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—DHFR—bone cancer	0.000119	0.000573	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—DHFR—bone cancer	0.000118	0.000568	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—GNA11—bone cancer	0.000111	0.000536	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—GNA11—bone cancer	0.00011	0.000531	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—CYP3A4—bone cancer	0.00011	0.000528	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000109	0.000525	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—ENO2—bone cancer	0.000109	0.000524	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—PTGS2—bone cancer	0.000103	0.000494	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—CYP3A4—bone cancer	0.000101	0.000486	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—DHFR—bone cancer	0.000101	0.000486	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—CYP3A4—bone cancer	9.99e-05	0.000482	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.94e-05	0.000479	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—GNA11—bone cancer	9.41e-05	0.000454	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—GSTP1—bone cancer	9.37e-05	0.000452	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—GSTP1—bone cancer	8.62e-05	0.000415	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—GSTP1—bone cancer	8.54e-05	0.000412	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—CYP3A4—bone cancer	8.54e-05	0.000412	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.49e-05	0.000409	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—GSTP1—bone cancer	7.3e-05	0.000352	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—PTGS2—bone cancer	4.85e-05	0.000234	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—PTGS2—bone cancer	4.46e-05	0.000215	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—PTGS2—bone cancer	4.43e-05	0.000213	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—PTGS2—bone cancer	3.78e-05	0.000182	CbGpPWpGaD
